Table 1 Information from the nine articles about coverage of the four selected non-NIP vaccines
Vaccine | Authors and affiliations | Duration | Sample size | Methods | Study sites | Overall rate (%, 95% CI) | Regional disparity (%, 95% CI) |
|---|---|---|---|---|---|---|---|
Hib vaccine | Li et al. [34]b | 2006–2016 | 29 papers | Systematic review and meta-analysis | 13 provincial-level administrative divisions (PLADs) | The pooled vaccination rate for at least one dose: 55.9, 52.3–59.4 | Eastern (62.9, 58.8–67.0); central and western (48.1,40.5–55.6) |
Li et al. [35]a | 2014 | 978 people | Multi-stage sampling survey | 8 PLADs | 44.8 (43.2–46.4) for at least one dose vaccination rate | Children in developed areas received 3 or more doses, while most children received 1 dose in underdeveloped areas | |
Yang et al. [36]b | 2007–2016 | 33 papers | Systematic review and meta-analysis | 12 PLADs | The pooled overall coverage for at least one dose: 54.9,52.9–57.0 | Eastern (59.7, 57.3–62.1); central and western (48.5,40.6–56.4) | |
Lai et al. [37]b | 2019 | 6668 people | Multi-stage sampling survey | 10 PLADs | 33.4 for three-dose at the national level in 2017 | Eastern (38.1); Central (34.3); Western (26.2) | |
Zhang et al. [38]b | 2019 | 5294 people | 10 PLADs | Hib1(42.6, 41.3–44.0), Hib3 (25.0, 23.7–26.3) | The coverage in developed areas is generally higher than that in underdeveloped areas in 10 provinces | ||
HPV vaccine | Song et al. [39]a | 2018–2020 | NA | Analysis of routine statistics data | 31 PLADs | The estimated three-dose cumulative coverage in the year 2018, 2019, 2020 (0.3, 1.0, 2.2) | Beijing (8.3), Shanghai (7.4), Xinjiang (0.5), Qinghai (0.4), Tibet (0.1) in 2020 |
PCV vaccine | Yue et al. [40]a | 2014 | 978 people | Multi-stage sampling survey | 8 PLADs | 16.9 for one dose of PPSV23 vaccination | N/A |
Shao et al. [41]b | 2013–2021 | 76 papers | Systematic review and meta-analysis | NA | The summary PCV vaccine coverage: 21.7,17.2–26.5 | Eastern (22.8, 17.7–28.5) Central (22.1, 8.5–35.4) Western (19.8, 9.0–37.6) | |
Lai et al. [37]b | 2019 | 6668 people | Multi-stage sampling survey | 10 PLADs | 1.3 for three-dose at the national level in 2017 | Eastern (2.5); Central (0.6); Western (0.7) | |
Zhang et al. [38]b | 2019 | 5294 people | 10 PLADs | PCV1(7.7,6.9–8.4), PCV3(5.1, 4.5–5.8) | The coverage in developed areas is generally higher than that in underdeveloped areas in 10 provinces | ||
Rotavirus vaccine | Liu et al. [42]a | 2014 | 606 people | Multi-stage sampling survey | 6 PLADs | Rota1, Rota2, Rota3 (32.8, 9.7, 3.5) | One dose of rotavirus vaccine in high, middle, and low-income areas (45.0, 37.7, 15.5) |
Zhang et al. [38]b | 2019 | 5294 people | 10 PLADs | Rota1 (20.3, 19.2–21.3) Rota3 (1.8, 1.3–2.2) | The coverage in developed areas is generally higher than that in underdeveloped areas in 10 provinces |